Sangamo Therapeutics Inc banner

Sangamo Therapeutics Inc
XMUN:GBY

Watchlist Manager
Sangamo Therapeutics Inc Logo
Sangamo Therapeutics Inc
XMUN:GBY
Watchlist
Price: 0.1234 EUR Market Closed
Market Cap: €187.3m

Wall St Price Targets

GBY Price Targets Summary
Sangamo Therapeutics Inc

There are no price targets for GBY.
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
Sangamo Therapeutics Inc Competitors:
Price Targets
VRNS
Varonis Systems Inc
15% Upside
NNOX
Nano-X Imaging Ltd
427% Upside
1981
Cathay Media and Education Group Inc
70% Upside
LVO
LiveOne Inc
160% Upside

Revenue
Forecast

5% / Year
Past Growth
90% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
5% / Year
Past Growth
90% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 5%. The projected CAGR for the next 3 years is 90%.

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is GBY's stock price target?
Not Available

GBY does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for Sangamo Therapeutics Inc?
Projected CAGR
90%

Over the last 13 years, the compound annual growth rate for Revenue has been 5%. The projected CAGR for the next 3 years is 90%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett